Roger Jeffs Sells 32,744 Shares of Liquidia (NASDAQ:LQDA) Stock

Liquidia Corporation (NASDAQ:LQDA) CEO Roger Jeffs sold 32,744 shares of Liquidia stock in a transaction dated Monday, April 13th. The shares were sold at an average price of $38.37, for a total transaction of $1,256,387.28. Following the completion of the transaction, the chief executive officer directly owned 1,137,599 shares of the company’s stock, valued at $43,649,673.63. This trade represents a 2.80% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Roger Jeffs also recently made the following trade(s):

• On Friday, April 10th, Roger Jeffs sold 21,433 shares of Liquidia stock. The shares were sold at an average price of $40.12, for a total transaction of $859,891.96.
• On Thursday, April 9th, Roger Jeffs sold 25,000 shares of Liquidia stock. The shares were sold at an average price of $40.12, for a total transaction of $1,003,000.00.

Liquidia Trading Up 3.6%

NASDAQ LQDA opened at $40.12 on Thursday. Liquidia Corporation has a one year low of $11.85 and a one year high of $46.67. The company has a 50-day simple moving average of $36.63 and a 200-day simple moving average of $33.08. The company has a debt-to-equity ratio of 2.97, a quick ratio of 1.84 and a current ratio of 2.01. The firm has a market capitalization of $3.53 billion, a PE ratio of -48.34 and a beta of 0.45.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings results on Thursday, March 5th. The company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.08 by $0.07. Liquidia had a negative net margin of 43.53% and a negative return on equity of 209.33%. The company had revenue of $92.02 million during the quarter, compared to the consensus estimate of $87.49 million. The company’s revenue for the quarter was up 3072.4% on a year-over-year basis. On average, equities analysts forecast that Liquidia Corporation will post -1.51 earnings per share for the current year.

Institutional Investors Weigh In On Liquidia

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Seven Fleet Capital Management LP bought a new stake in shares of Liquidia during the fourth quarter valued at about $3,148,000. Invesco Ltd. raised its stake in shares of Liquidia by 428.3% during the fourth quarter. Invesco Ltd. now owns 420,621 shares of the company’s stock valued at $14,507,000 after purchasing an additional 341,009 shares in the last quarter. XTX Topco Ltd bought a new stake in shares of Liquidia during the fourth quarter valued at about $1,214,000. nVerses Capital LLC bought a new stake in shares of Liquidia during the fourth quarter valued at about $335,000. Finally, Occudo Quantitative Strategies LP bought a new stake in shares of Liquidia during the fourth quarter valued at about $3,107,000. 64.54% of the stock is currently owned by institutional investors.

Key Headlines Impacting Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia reported an earnings beat for the quarter ended Mar 5 (revenue and EPS above consensus), which supports near‑term fundamentals and helps justify analyst upside. Read More.
• Positive Sentiment: Several brokers have reiterated or raised bullish views and price targets (multiple buy / strong‑buy ratings and target upgrades), providing analyst support for the stock’s rally. Read More.
• Neutral Sentiment: Institutional ownership is substantial (~64.5%), and some funds have added modest positions recently — this can mute volatility from insider selling if institutions hold. Read More.
• Negative Sentiment: Broad insider selling: multiple insiders (CEO Roger Jeffs, CFO Michael Kaseta, General Counsel Russell Schundler, CAO Dana Boyle and others) disclosed sales between Apr 9–13. Many filings say the trades were under 10b5‑1 plans and to cover tax withholding on vested awards, but the pattern can still weigh on sentiment near recent highs. Read More.
• Negative Sentiment: Notable large block: CFO Michael Kaseta disclosed a 133,789‑share sale (reported earlier in filings), a materially sizeable reduction that may attract extra scrutiny about insider conviction despite stated tax/10b5‑1 reasons. Read More.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Liquidia in a report on Thursday, January 22nd. Needham & Company LLC boosted their price target on shares of Liquidia from $52.00 to $54.00 and gave the company a “buy” rating in a report on Thursday, March 5th. Wells Fargo & Company boosted their price target on shares of Liquidia from $44.00 to $51.00 and gave the company an “overweight” rating in a report on Monday, March 23rd. Lifesci Capital raised shares of Liquidia to a “strong-buy” rating in a report on Thursday, March 5th. Finally, BTIG Research boosted their price target on shares of Liquidia from $49.00 to $50.00 and gave the company a “buy” rating in a report on Thursday, March 5th. Two research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $43.44.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).